Gamco Investors INC. ET AL Sells 850 Shares of Davita Inc (NYSE:DVA)

Gamco Investors INC. ET AL lessened its holdings in Davita Inc (NYSE:DVA) by 2.5% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 32,806 shares of the company’s stock after selling 850 shares during the period. Gamco Investors INC. ET AL’s holdings in Davita were worth $1,872,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of DVA. Amundi Pioneer Asset Management Inc. lifted its stake in shares of Davita by 31.9% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 154,693 shares of the company’s stock worth $8,398,000 after purchasing an additional 37,375 shares during the period. Denali Advisors LLC raised its stake in Davita by 215.3% during the 2nd quarter. Denali Advisors LLC now owns 18,600 shares of the company’s stock worth $1,046,000 after acquiring an additional 12,700 shares during the period. Retirement Systems of Alabama raised its stake in Davita by 10.7% during the 2nd quarter. Retirement Systems of Alabama now owns 175,076 shares of the company’s stock worth $9,850,000 after acquiring an additional 16,869 shares during the period. Campbell & CO Investment Adviser LLC bought a new stake in Davita during the 2nd quarter worth approximately $493,000. Finally, Rothschild Investment Corp IL bought a new stake in Davita during the 2nd quarter worth approximately $735,000. Hedge funds and other institutional investors own 91.00% of the company’s stock.

DVA traded up $0.66 during trading on Friday, reaching $69.85. 2,446,213 shares of the company traded hands, compared to its average volume of 2,127,695. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.10 and a current ratio of 1.12. Davita Inc has a 12-month low of $43.40 and a 12-month high of $70.51. The firm has a fifty day simple moving average of $58.51 and a 200 day simple moving average of $55.70. The company has a market cap of $10.01 billion, a P/E ratio of 19.57, a PEG ratio of 0.62 and a beta of 1.59.

Davita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $1.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.24 by $0.29. Davita had a net margin of 3.68% and a return on equity of 18.03%. The business had revenue of $2.90 billion during the quarter, compared to analyst estimates of $2.85 billion. During the same period last year, the firm posted $0.56 EPS. The company’s revenue was up 2.0% on a year-over-year basis. As a group, sell-side analysts expect that Davita Inc will post 5.19 earnings per share for the current fiscal year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

A number of equities research analysts have issued reports on DVA shares. UBS Group cut their price objective on shares of Davita from $61.00 to $60.00 and set a “neutral” rating for the company in a report on Thursday, August 22nd. ValuEngine raised shares of Davita from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. William Blair lowered shares of Davita from an “outperform” rating to a “market perform” rating in a report on Wednesday, September 11th. SunTrust Banks increased their price objective on shares of Davita to $72.00 and gave the company a “hold” rating in a report on Wednesday. Finally, Raymond James lowered shares of Davita from an “outperform” rating to a “market perform” rating in a report on Thursday. Nine equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $64.81.

Davita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Featured Story: What are the disadvantages of after-hours trading?

Institutional Ownership by Quarter for Davita (NYSE:DVA)

Leave a Reply

Your email address will not be published. Required fields are marked *

*